Videos de Experimentos Relacionados
El uso de "drogas diseñadas racionalmente" de manera racional.
Jim Brugarolas1, Jeffrey W Clark, Bruce Chabner
1Dana Farber Cancer Institute, Boston, MA 02115, USA. james_brugarolas@dfci.harvard.edu <james_brugarolas@dfci.harvard.edu>
Lancet (London, England)
|June 5, 2003
Resumen
No abstract available in PubMed .
Videos de Conceptos Relacionados
También podría leer
Artículos Relacionados
Artículos vinculados a este trabajo por autores compartidos, revista y gráfico de citas.
Ordenar por
Same author
Biochemistry at scale: Seeing both the forest and the trees.
Trends in biochemical sciences·2026
Same author
Neoadjuvant stereotactic body radiation therapy plus immune therapy favorably remodels the hepatocellular carcinoma tumor microenvironment.
Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same author
Open-Label, Phase II Trial of Extracellular Regulated Kinase Inhibition Alone and in Combination With Autophagy Inhibition in Patients With Metastatic Pancreatic Cancer.
JCO precision oncology·2025
Same author
Protected Time, Resources, and Expectations for Academic Oncology Clinical Research Physicians.
Journal of the National Comprehensive Cancer Network : JNCCN·2025
Same author
Long-term Outcomes of Definitive Chemoradiation With Proton Therapy for Treatment of Carcinoma of the Anal Canal: Combined Analysis of Two Prospective Trials.
International journal of radiation oncology, biology, physics·2025
Same author
Hypofractionated Radiotherapy-Related Lymphopenia Is Associated With Worse Survival in Unresectable Intrahepatic Cholangiocarcinoma.
American journal of clinical oncology·2024
Same journal
Assisted dying and the silencing of medicine's next generation.
Lancet (London, England)·2026
Same journal
Linguistic pragmatism: a woman with progressive abdominal pain in Thailand.
Lancet (London, England)·2026
Same journal
Medical compartmentalisation: a patient with chromosome 22q11.2 deletion syndrome in Japan.
Lancet (London, England)·2026
Same journal
[<sup>177</sup>Lu]Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): a phase 3, multicentre, randomised, open-label, superiority trial.
Lancet (London, England)·2026
Same journal
Rethinking treatment sequence in advanced gastroenteropancreatic neuroendocrine tumours.
Lancet (London, England)·2026